NCT02338245

Who might be able to join this trial:

• You have been diagnosed with breast cancer that has been confirmed by a tissue sample (biopsy), and your cancer tests positive for a protein called HER2 (meaning HER2 is overexpressed or the gene is amplified).
• You have HER2-positive breast cancer that has spread to other parts of the body (metastatic), and either a previous first-line treatment with a drug called trastuzumab (Herceptin) did not work, or your cancer came back within 1 year of receiving trastuzumab as an early-stage treatment.
• At least one area of your cancer can be measured on a scan (note: bone-only spread or fluid build-up in the abdomen alone would not count as measurable).
• You are at or above the legal adult age in your country at the time you sign the consent form.
• Your organs (such as kidneys and liver) and blood counts are at acceptable levels.

Who may not be able to join:

• You have had radiation therapy or a major operation within the last 21 days before joining the trial.
• You have a condition that affects how your body absorbs food or medication, such as problems with your stomach or small intestine, or you have difficulty swallowing and keeping oral medications down.
• You have an illness that is not well controlled, such as an active infection, unstable chest pain (angina), irregular heartbeat, uncontrolled diabetes, uncontrolled high blood pressure, or a mental health or personal situation that might make it hard to follow the trial requirements.
• You have had another type of cancer in the past, unless you have been cancer-free for more than 1 year (certain skin cancers and a specific type of early cervical cancer that were fully treated are generally not excluded — confirm with trial site).
• You have cancer that has spread to your brain and is causing symptoms, or you have taken steroid medications or anti-seizure medications for this reason within the past 3 months.
• You are currently pregnant or breastfeeding.
• You have previously been treated with either of the study drugs: ASLAN001 or lapatinib.
• You have already received more than 2 rounds (lines) of treatment for your metastatic breast cancer.
• You have taken another experimental drug or used an experimental device within the last 21 days, or received certain antibody-based cancer treatments within a specific timeframe before starting the trial (confirm exact timeframe with trial site).
• You still have serious, unresolved side effects from a previous experimental drug or cancer treatment.

Important: Always verify eligibility with the trial site directly before applying.